Literature DB >> 19406100

Arginine 383 is a crucial residue in ABCG2 biogenesis.

Orsolya Polgar1, Lilangi S Ediriwickrema, Robert W Robey, Ajay Sharma, Ramanujan S Hegde, Yongfu Li, Di Xia, Yvona Ward, Michael Dean, Csilla Ozvegy-Laczka, Balazs Sarkadi, Susan E Bates.   

Abstract

ABCG2 is an ATP-binding cassette half-transporter initially identified in multidrug-resistant cancer cell lines and recently suggested to play an important role in pharmacokinetics. Here we report studies of a conserved arginine predicted to localize near the cytoplasmic side of TM1. First, we determined the effect of losing charge and bulk at this position via substitutions with glycine and alanine. The R383G mutant when transfected into HEK cells was not detectable on immunoblot or by functional assay, while the R383A mutant exhibited detectable but significantly decreased levels compared to wild-type, partial retention in the ER and altered glycosylation. Efflux of the ABCG2-substrates mitoxantrone and pheophorbide a was observed. Our experiments suggested rapid degradation of the R383A mutant by the proteasome via a kifunensine-insensitive pathway. Interestingly, overnight treatment of the R383A mutant with mitoxantrone assisted in protein maturation as evidenced by a shift to the N-glycosylated form. The R383A mutant when expressed in insect cells, though detected on the surface, had no measurable ATPase activity. In addition, substitution with the positively charged lysine resulted in significantly decreased protein expression levels in HEK cells, while retaining function. In conclusion, arginine 383 is a crucial residue for ABCG2 biogenesis, where even the most conservative mutations have a large impact.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19406100      PMCID: PMC4163909          DOI: 10.1016/j.bbamem.2009.04.016

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  66 in total

1.  Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.

Authors:  Csilla Ozvegy-Laczka; György Várady; Gabriella Köblös; Olga Ujhelly; Judit Cervenak; John D Schuetz; Brian P Sorrentino; Gerrit-Jan Koomen; András Váradi; Katalin Német; Balázs Sarkadi
Journal:  J Biol Chem       Date:  2004-11-22       Impact factor: 5.157

2.  Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.

Authors:  Csilla Ozvegy-Laczka; Gabriella Köblös; Balázs Sarkadi; András Váradi
Journal:  Biochim Biophys Acta       Date:  2005-02-01

3.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.

Authors:  K Miyake; L Mickley; T Litman; Z Zhan; R Robey; B Cristensen; M Brangi; L Greenberger; M Dean; T Fojo; S E Bates
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

Review 4.  Insect cells as hosts for the expression of recombinant glycoproteins.

Authors:  F Altmann; E Staudacher; I B Wilson; L März
Journal:  Glycoconj J       Date:  1999-02       Impact factor: 2.916

5.  Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

Authors:  M Maliepaard; M A van Gastelen; L A de Jong; D Pluim; R C van Waardenburg; M C Ruevekamp-Helmers; B G Floot; J H Schellens
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

6.  Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.

Authors:  Ulla Henriksen; Ulrik Gether; Thomas Litman
Journal:  J Cell Sci       Date:  2005-03-15       Impact factor: 5.285

7.  N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane.

Authors:  Ndeye K Diop; Christine A Hrycyna
Journal:  Biochemistry       Date:  2005-04-12       Impact factor: 3.162

8.  ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

Authors:  Jeffrey A Engelman; Pasi A Jänne; Craig Mermel; Joseph Pearlberg; Toru Mukohara; Christina Fleet; Karen Cichowski; Bruce E Johnson; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-24       Impact factor: 11.205

9.  Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

Authors:  N Barry Elkind; Zsófia Szentpétery; Agota Apáti; Csilla Ozvegy-Laczka; György Várady; Olga Ujhelly; Katalin Szabó; László Homolya; András Váradi; László Buday; György Kéri; Katalin Német; Balázs Sarkadi
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

10.  Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2.

Authors:  Hiroshi Nakagawa; Ai Tamura; Kanako Wakabayashi; Kazuyuki Hoshijima; Masayuki Komada; Takashi Yoshida; Satoshi Kometani; Takayoshi Matsubara; Kenta Mikuriya; Toshihisa Ishikawa
Journal:  Biochem J       Date:  2008-05-01       Impact factor: 3.857

View more
  16 in total

1.  Posttranslational negative regulation of glycosylated and non-glycosylated BCRP expression by Derlin-1.

Authors:  Takashi Sugiyama; Tsuyoshi Shuto; Shingo Suzuki; Takashi Sato; Tomoaki Koga; Mary Ann Suico; Hiroyuki Kusuhara; Yuichi Sugiyama; Douglas M Cyr; Hirofumi Kai
Journal:  Biochem Biophys Res Commun       Date:  2010-12-22       Impact factor: 3.575

Review 2.  Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).

Authors:  Zhanglin Ni; Zsolt Bikadi; Mark F Rosenberg; Qingcheng Mao
Journal:  Curr Drug Metab       Date:  2010-09       Impact factor: 3.731

3.  Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.

Authors:  Zhanglin Ni; Zsolt Bikadi; Xiaokun Cai; Mark F Rosenberg; Qingcheng Mao
Journal:  Am J Physiol Cell Physiol       Date:  2010-08-25       Impact factor: 4.249

4.  Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport.

Authors:  Xiaokun Cai; Zsolt Bikadi; Zhanglin Ni; Eun-Woo Lee; Honggang Wang; Mark F Rosenberg; Qingcheng Mao
Journal:  J Pharmacol Exp Ther       Date:  2010-03-04       Impact factor: 4.030

Review 5.  The challenge of exploiting ABCG2 in the clinic.

Authors:  Robert W Robey; Caterina Ierano; Zhirong Zhan; Susan E Bates
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

6.  Mutation of Glu521 or Glu535 in cytoplasmic loop 5 causes differential misfolding in multiple domains of multidrug and organic anion transporter MRP1 (ABCC1).

Authors:  Surtaj H Iram; Susan P C Cole
Journal:  J Biol Chem       Date:  2012-01-09       Impact factor: 5.157

7.  Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2.

Authors:  Orsolya Polgar; Caterina Ierano; Akina Tamaki; Bradford Stanley; Yvona Ward; Di Xia; Nadya Tarasova; Robert W Robey; Susan E Bates
Journal:  Biochemistry       Date:  2010-03-16       Impact factor: 3.162

8.  Identification of residues in ABCG2 affecting protein trafficking and drug transport, using co-evolutionary analysis of ABCG sequences.

Authors:  Ameena J Haider; Megan H Cox; Natalie Jones; Alice J Goode; Katherine S Bridge; Kelvin Wong; Deborah Briggs; Ian D Kerr
Journal:  Biosci Rep       Date:  2015-07-17       Impact factor: 3.840

9.  Jump into a New Fold-A Homology Based Model for the ABCG2/BCRP Multidrug Transporter.

Authors:  Laura László; Balázs Sarkadi; Tamás Hegedűs
Journal:  PLoS One       Date:  2016-10-14       Impact factor: 3.240

10.  The structure of the human ABC transporter ABCG2 reveals a novel mechanism for drug extrusion.

Authors:  Narakorn Khunweeraphong; Thomas Stockner; Karl Kuchler
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.